Enzalutamide + Placebo + Androgen deprivation therapy (ADT)
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Hormone Sensitive Prostate Cancer
Conditions
Metastatic Hormone Sensitive Prostate Cancer
Trial Timeline
Sep 11, 2019 → Dec 31, 2028
NCT ID
NCT04076059About Enzalutamide + Placebo + Androgen deprivation therapy (ADT)
Enzalutamide + Placebo + Androgen deprivation therapy (ADT) is a phase 3 stage product being developed by Astellas Pharma for Metastatic Hormone Sensitive Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04076059. Target conditions include Metastatic Hormone Sensitive Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Hormone Sensitive Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04076059 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Hormone Sensitive Prostate Cancer